Kamada Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Kamada Ltd. on November 17, 2015, for the month of November 2015. The filing serves as a report of a foreign private issuer pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 and is incorporated by reference into the company's Form S-8 Registration Statement.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, or overall liquidity. The only specific financial metric disclosed relates to the company's Series C Debentures:
- Series C Debenture Interest Rate: 1.54744% for the period from September 1, 2015, to November 30, 2015.
- Annualized Interest Rate: 6.18976%.
- Payment Date: December 1, 2015.
- Record Date: November 19, 2015.
- Ex-Date: November 19, 2015.
Material Changes
The filing does not disclose material changes in financial performance or operations compared to prior periods. It solely announces the specific interest rate applicable to the Series C Debentures for the current quarter.
Guidance, Outlook, and Risks
The document includes a cautionary note regarding forward-looking statements. Management notes that actual results may differ materially from expectations due to several risks, including:
- Unexpected results of clinical trials.
- Delays or denial in U.S. FDA or EMA approval processes.
- Additional competition in the Alpha-1 Antitrypsin Deficiency (AATD) market.
- Further regulatory delays.
The company states it undertakes no obligation to update these forward-looking statements except as required by law.
Investor Verification Checklist
- Verify the record date (November 19, 2015) to confirm eligibility for the upcoming interest payment.
- Confirm the payment date of December 1, 2015, for Series C Debenture holders.
- Review the company's latest Form 20-F for comprehensive financial statements, as this 6-K contains no revenue or earnings data.
- Monitor regulatory updates regarding FDA and EMA approvals for the company's clinical pipeline.